Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Accumulated Expenses (2022 - 2025)

Historic Accumulated Expenses for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $48.2 million.

  • Day One Biopharmaceuticals' Accumulated Expenses rose 3700.3% to $48.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.2 million, marking a year-over-year increase of 3700.3%. This contributed to the annual value of $68.6 million for FY2024, which is 15872.79% up from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Accumulated Expenses of $48.2 million as of Q3 2025, which was up 3700.3% from $44.1 million recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Accumulated Expenses registered a high of $87.1 million during Q2 2024, and its lowest value of $7.3 million during Q1 2022.
  • Over the past 4 years, Day One Biopharmaceuticals' median Accumulated Expenses value was $24.8 million (recorded in 2024), while the average stood at $32.3 million.
  • In the last 5 years, Day One Biopharmaceuticals' Accumulated Expenses skyrocketed by 34608.84% in 2024 and then plummeted by 4931.67% in 2025.
  • Day One Biopharmaceuticals' Accumulated Expenses (Quarter) stood at $16.0 million in 2022, then surged by 66.29% to $26.5 million in 2023, then soared by 158.73% to $68.6 million in 2024, then decreased by 29.75% to $48.2 million in 2025.
  • Its Accumulated Expenses was $48.2 million in Q3 2025, compared to $44.1 million in Q2 2025 and $43.6 million in Q1 2025.